Phase IIa (therapeutic exploratory), multicenter, randomized, double-blind, placebocontrolled, 2-stage, 4-arm study exploring the effect of BST204 on cancer-related cachexia in patients with gastrointestinal or non-small-cell lung cancer

Start Date15 Jan 2018

Sponsor / Collaborator

GREEN CROSS WellBeing Corp.

100 Clinical Results associated with BST-204

100 Translational Medicine associated with BST-204

100 Patents (Medical) associated with BST-204

Literatures (Medical) associated with BST-204

01 Sep 2023·Biochemistry and Biophysics Reports

Effects of the purified dry extract of fermented ginseng BST204 on muscle fiber regeneration

Article

Author: Bae, SangMun ; Lee, Slee ; Lee, Hyejin ; Kim, Do Yeon ; Moon, Jai-Hee ; Jo, Su In ; Park, Yoon Sun ; Chang, Yeeun ; Im, Minju ; Park, Se Yeong ; You, Ji-Eun ; Jin, Dong-Hoon ; Kim, Sang-Yeob ; Kim, MiYeon ; Han, Hae-Jung ; Yun, Hyeseon

BackgroundSarcopenia and muscular dystrophy are two muscle diseases. In cancer patients, cancer cachexia induces continuous weight loss and muscle loss due to the disease itself or the use of anticancer drugs. Cachexia occurs in up to 80% of cancer patients. It is recognized as a direct cause of reduced quality of life, contributing to at least 20% of cancer-associated deaths and limiting therapeutic options for cancer patients. Cancer cachexia is associated with multiple chronic or end-stage conditions and develops similarly. There are various options for the treatment of cancer cachexia, but there are still many issues to be solved. Hence, to determine its potential to overcome the muscle wasting during cancer cachexia, we studied the effect of BST204, a refined dry ginseng extract, on muscle fiber regeneration.Experimental procedureWe checked the muscle regeneration efficacy of BST204. First, BaCl₂ and freeze injury models were selected to investigate muscle regeneration after BST204 administration. In addition, after inducing muscle differentiation of C2C12 cells, the efficacy of BST204 was analyzed. In this model, we analyzed the expression of the signal pathway (PI3K-AKT signal) by Western blot and imaging methods.Results and conclusionThese results showed that BST204 induced muscle fiber regeneration in BaCl₂ and freeze injury models. Also, we confirmed that BST204 could regulate the PI3K/AKT signaling pathway and regulate the differentiation of C2C12 cells. These results indicate that BST204 has the potential to facilitate the skeletal muscle regeneration during muscle wasting induced by various factors including cancer cachexia.

01 Apr 2021·MetabolomicsQ3 · MEDICINE

Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study

Q3 · MEDICINE

Article

Author: Kim, Jeom-Yong ; Kim, Jeong Kon ; Woo, Dong-Cheol ; Kim, Su Jung ; Kim, Ho-Jin ; Park, Sun Kyu ; Yoo, Hyun Ju ; Kim, Sang-Tae ; Woo, Chul-Woong ; Im, Minju

INTRODUCTIONChemotherapy is a major etiology of cachexia. Ginseng products are known to have various anti-cachectic and health-promoting effects, such as inhibiting inflammation and promoting energy production. In particular, BST204, purified ginseng dry extract, contains multiple ginsenosides that can reduce chemotherapy-related fatigue and toxicity.OBJECTIVESTo investigate the effects of BST204 on the alleviation of chemotherapy-induced cachexia using a multimodal approach.METHODSIn a CT26 mouse syngeneic colon cancer model, cachexia was predominantly induced by chemotherapy with 5-fluorouracil (5-FU) than by tumor growth. BST204 at a dose of 100 or 200 mg/kg was administered to 5-FU-treated mice.RESULTSBST204 significantly mitigated the decrease in tumor-excluded body weight (change in 5-FU group and BST204 groups: - 13% vs. - 6% on day 7; - 30% vs. - 20% on day 11), muscle volume (- 19% vs. - 11%), and fat volume (- 91% vs. - 56%). The anti-cachectic effect of BST204 was histologically demonstrated by an improved balance between muscle regeneration and degeneration and a decrease in muscle cross-sectional area reduction.CONCLUSIONChemotherapy-induced cachexia was biochemically and metabolically characterized by activated inflammation, enhanced oxidative stress, increased protein degradation, decreased protein stabilization, reduced glucose-mediated energy production, and deactivated glucose-mediated biosynthesis. These adverse effects were significantly improved by BST204 treatment. Overall, our multimodal study demonstrated that BST204 could effectively alleviate chemotherapy-induced cachexia.

01 Jan 2020·The American Journal of Chinese MedicineQ2 · MEDICINE

BST204, a Rg3 and Rh2 Enriched Ginseng Extract, Upregulates Myotube Formation and Mitochondrial Function in TNF-α-Induced Atrophic Myotubes

Q2 · MEDICINE

Article

Author: Im, Minju ; Lee, Sang-Jin ; Kim, Jeom-Yong ; Park, Sun Kyu ; Liang, Olin D. ; Kang, Jong-Sun ; So, Eui-Young ; Bae, Gyu-Un

The loss of skeletal muscle mass and function is a serious consequence of chronic diseases and aging. BST204 is a purified ginseng (the root of Panax ginseng) extract that has been processed using ginsenoside-[Formula: see text]-glucosidase and acid hydrolysis to enrich ginsenosides Rg3 and Rh2 from the crude ginseng. BST204 has a broad range of health benefits, but its effects and mechanism on muscle atrophy are currently unknown. In this study, we have examined the effects and underlying mechanisms of BST204 on myotube formation and myotube atrophy induced by tumor necrosis factor-[Formula: see text] (TNF-[Formula: see text]). BST204 promotes myogenic differentiation and multinucleated myotube formation through Akt activation. BST204 prevents myotube atrophy induced by TNF-[Formula: see text] through the activation of Akt/mTOR signaling and down-regulation of muscle-specific ubiquitin ligases, MuRF1, and Atrogin-1. Furthermore, BST204 treatment in atrophic myotubes suppresses mitochondrial reactive oxygen species (ROS) production and regulates mitochondrial transcription factors such as NRF1 and Tfam, through enhancing the activity and expression of peroxisome proliferator-activated receptor-[Formula: see text] coactivator1[Formula: see text] (PGC1[Formula: see text]). Collectively, our findings indicate that BST204 improves myotube formation and PGC1[Formula: see text]-mediated mitochondrial function, suggesting that BST204 is a potential therapeutic or neutraceutical remedy to intervene muscle weakness and atrophy.

100 Deals associated with BST-204

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cachexia	Phase 2	EU	GREEN CROSS WellBeing Corp.	-
Neoplasms	Phase 1	-	Kwang Dong Pharmaceutical Co., Ltd.	-
Neoplasms	Phase 1	-	Green Cross Holdings Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

BST-204

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation